Yumanity Therapeutics Inc expected to post a loss of 95  cents a share - Earnings Preview

Kineta

09/05/2022 19:32

* Yumanity Therapeutics Inc  YMTX.OQ   YMTX.O  is expected
to show
a fall in quarterly revenue when it reports  results on May 11
(estimated). 
    * The Boston Massachusetts-based  company is expected to
report  a
43.4% decrease in revenue to $2 million from $3.53 million a
year ago, according to the estimate from one analyst, based on
Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Yumanity
Therapeutics Inc
is for a loss of 95 cents per share. For the same quarter last
year, the company reported a loss of 85 cents per share.
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Yumanity
Therapeutics Inc is $35​, above​ its last closing price
of $1.20. ​​​

This summary was machine generated May 9 at 18:31 GMT.  All
figures in US dollars  unless otherwise stated